文献速递流行病学与生物统计真实世界研究与卫生经济

延迟抗生素处方治疗呼吸道感染:个体患者数据荟萃分析

Delayed antibiotic prescribing for respiratory tract infections: individual patient data meta-analysis.
PubMed 文献 · BMJ · 2021-04-28

结果显示延迟处方在症状严重程度、病程和并发症方面与立即处方或无处方相似或更优,可减少再就诊率并提高满意度,但5岁以下儿童症状严重度略高。

要点

  • 延迟抗生素处方对多数呼吸道感染患者安全有效,症状控制不劣于立即处方。
  • 延迟处方可减少再就诊率并提高患者满意度,不增加并发症风险。
  • 5岁以下儿童使用延迟处方时症状严重度略高于立即处方,需关注。

核心结论

  • 延迟抗生素处方是多数呼吸道感染患者的安全有效策略,包括较高风险亚组。
  • 延迟处方的症状持续时间与无抗生素处方相似,不太可能导致症状控制差于立即处方。
  • 延迟处方可减少再就诊率,除幼儿外不太可能增加症状或病程。

研究设计与样本

  • 系统综述与个体患者数据荟萃分析,检索Cochrane Central、Medline、Embase、CINAHL Plus和Web of Science。
  • 比较延迟抗生素与无抗生素处方,以及延迟与立即抗生素处方。

主要发现

  • 延迟与立即抗生素处方的随访症状严重度(7分制)无差异:调整均数差-0.003(95%CI -0.12至0.11)。
  • 延迟与无抗生素处方的随访症状严重度无差异:调整均数差0.02(95%CI -0.11至0.15)。
  • 延迟处方的症状持续时间略长于立即抗生素(11.4天 vs 10.9天),但与无抗生素相似。
  • 延迟与无抗生素相比,再就诊率降低(OR 0.72,95%CI 0.60至0.87),患者满意度提高(调整均数差0.09,95%CI 0.06至0.11)。
  • 5岁以下儿童延迟处方的随访症状严重度略高于立即抗生素(调整均数差0.10,95%CI 0.03至0.18)。

关键数值与推荐

  • 主要结局为初诊后2至4天的平均症状严重度,采用7项量表(从正常到最差)。
  • 延迟与无抗生素相比,导致住院或死亡的并发症OR 0.62(95%CI 0.30至1.27)。
  • 延迟与立即抗生素相比,导致住院或死亡的并发症OR 0.78(95%CI 0.53至1.13)。
  • 延迟与立即抗生素及延迟与无抗生素的效果不受既往病程、发热、合并症或症状严重度影响。

临床怎么用

  • 对多数社区呼吸道感染患者,可考虑延迟抗生素处方策略以平衡症状控制与抗生素合理使用。
  • 延迟处方有助于减少再就诊率并提高患者满意度,且不增加并发症风险。
  • 对5岁以下儿童使用延迟处方需谨慎,因其症状严重度可能略高于立即处方。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the overall effect of delayed antibiotic prescribing on average symptom severity for patients with respiratory tract infections in the community, and to identify any factors modifying this effect. DESIGN: Systematic review and individual patient data meta-analysis. DATA SOURCES: Cochrane Central Register of Controlled Trials, Ovid Medline, Ovid Embase, EBSCO CINAHL Plus, and Web of Science. ELIGIBILITY CRITERIA FOR STUDY SELECTION: Randomised controlled trials and observational cohort studies in a community setting that allowed comparison between delayed versus no antibiotic prescribing, and delayed versus immediate antibiotic prescribing. MAIN OUTCOME MEASURES: The primary outcome was the average symptom severity two to four days after the initial consultation measured on a seven item scale (ranging from normal to as bad as could be). Secondary outcomes were duration of illness after the initial consultation, complications resulting in admission to hospital or death, reconsultation with the same or worsening illness, and patient satisfaction rated on a Likert scale. RESULTS: Data were obtained from nine randomised controlled trials and four observational studies, totalling 55 682 patients. No difference was found in follow-up symptom severity (seven point scale) for delayed versus immediate antibiotics (adjusted mean difference -0.003, 95% confidence interval -0.12 to 0.11) or delayed versus no antibiotics (0.02, -0.11 to 0.15). Symptom duration was slightly longer in those given delayed versus immediate antibiotics (11.4 v 10.9 days), but was similar for delayed versus no antibiotics. Complications resulting in hospital admission or death were lower with delayed versus no antibiotics (odds ratio 0.62, 95% confidence interval 0.30 to 1.27) and delayed versus immediate antibiotics (0.78, 0.53 to 1.13). A significant reduction in reconsultation rates (odds ratio 0.72, 95% confidence interval 0.60 to 0.87) and an increase in patient satisfaction (adjusted mean difference 0.09, 0.06 to 0.11) were observed in delayed versus no antibiotics. The effect of delayed versus immediate antibiotics and delayed versus no antibiotics was not modified by previous duration of illness, fever, comorbidity, or severity of symptoms. Children younger than 5 years had a slightly higher follow-up symptom severity with delayed antibiotics than with immediate antibiotics (adjusted mean difference 0.10, 95% confidence interval 0.03 to 0.18), but no increased severity was found in the older age group. CONCLUSIONS: Delayed antibiotic prescribing is a safe and effective strategy for most patients, including those in higher risk subgroups. Delayed prescribing was associated with similar symptom duration as no antibiotic prescribing and is unlikely to lead to poorer symptom control than immediate antibiotic prescribing. Delayed prescribing could reduce reconsultation rates and is unlikely to be associated with an increase in symptoms or illness duration, except in young children. STUDY REGISTRATION: PROSPERO CRD42018079400.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Stuart B, Hounkpatin H, Becque T, et al. Delayed antibiotic prescribing for respiratory tract infections: individual patient data meta-analysis. BMJ. 2021. PMID: 33910882. doi:10.1136/bmj.n808

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。